EGFR酪氨酸激酶抑制剂联合立体定向体部放疗治疗IV期非小细胞肺癌:一项前瞻性多中心随机对照II期研究
这项前瞻性多中心随机对照II期研究纳入62例EGFR敏感突变(19DEL或21L858R)的IV期非小细胞肺癌患者,一线EGFR-TKI治疗3个月后疾病稳定或部分缓解者随机接受SBRT联合EGFR-TKI或单用EGFR-TKI。联合组中位无进展生存期17.6个月 vs 单药组9.0个月(HR=0.52,95%CI 0.31-0.89,P=0.016),中位总生存期33.6个月 vs 23.2个月(HR=0.53,95%CI 0.30-0.95,P=0.026)。两组均未观察到3级及以上毒性。
要点
- SBRT联合EGFR-TKI较单用EGFR-TKI显著延长IV期EGFR突变NSCLC的PFS和OS。
- 联合组中位PFS 17.6个月 vs 单药组9.0个月,HR=0.52(95%CI 0.31-0.89,P=0.016)。
- 两组均未观察到3级及以上毒性,2级不良事件联合组50% vs 单药组45.2%。
核心结论
- 加用SBRT显著延缓了EGFR-TKI获得性耐药的发生,并延长了患者的PFS和OS。
- 作者认为仅对原发灶进行放疗可能优于对转移灶放疗。
- 需要进一步的验证性研究来证实本研究发现。
研究设计与样本
- 前瞻性、随机、对照、II期研究,从中国武汉4家不同医院招募参与者。
- 纳入组织学确诊的IV期NSCLC且具有EGFR敏感突变(19DEL或21L858R)的患者,接受包括吉非替尼、厄洛替尼和埃克替尼的一线EGFR-TKI治疗3个月后达到疾病稳定或部分缓解者入组。
- 符合条件者按1:1随机分配接受SBRT联合EGFR-TKI或单用EGFR-TKI治疗。
- 联合组对不同肿瘤部位照射剂量为30-50 Gy分5次;考虑到SBRT duration短,放疗期间继续TKIs。
- 主要终点为无进展生存期(PFS),次要终点为总生存期(OS)和安全性;研究在ClinicalTrials.gov注册,注册号NCT03595644。
主要发现
- 2018年5月4日至2019年12月20日筛选74例患者,其中62例入组并随机化;因入组缓慢,研究在62/72例时提前关闭。
- 入组患者随机分配至SBRT联合EGFR-TKI组(n=31)或单用EGFR-TKI组(n=31);联合组1例随机化后拒绝接受SBRT,61例纳入改良意向治疗(mITT)分析,联合组30例、单药组31例。
- 截至临床 cutoff 日期(2022年2月14日),中位随访29.4个月(IQR 6.9-38.9)。
- EGFR-TKI组与SBRT联合组的中位PFS分别为9.0个月 vs 17.6个月(HR=0.52,95%CI 0.31-0.89,P=0.016)。
- 中位OS分别为23.2个月 vs 33.6个月(HR=0.53,95%CI 0.30-0.95,P=0.026);两组均未观察到3级及以上毒性,2级不良事件在EGFR-TKIs+SBRT组为50%,在EGFR-TKIs组为45.2%。
关键数值与推荐
- 联合组不同肿瘤部位照射剂量为30-50 Gy分5次。
- 主要终点PFS:单药组9.0个月 vs 联合组17.6个月(HR=0.52,95%CI 0.31-0.89,P=0.016)。
- 次要终点OS:单药组23.2个月 vs 联合组33.6个月(HR=0.53,95%CI 0.30-0.95,P=0.026)。
- 安全性:两组均未观察到3级及以上毒性;2级不良事件联合组50% vs 单药组45.2%。
临床怎么用
- 作者认为加用SBRT显著延缓了EGFR-TKI获得性耐药的发生,并延长了PFS和OS。
- 作者认为仅对原发灶进行放疗可能优于对转移灶放疗。
- 作者指出需要进一步的验证性研究来证实本研究发现。
局限性
- 研究因入组缓慢在62/72例时提前关闭。
- 1例随机分配至SBRT联合EGFR-TKI组的患者拒绝接受SBRT。
- 作者指出需要进一步的验证性研究来证实本研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant therapeutic effect in the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. However, the acquired resistance greatly limits the survival benefit of EGFR-TKIs for EGFR-mutant NSCLC patients. We aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus EGFR-TKIs in these patients. METHODS: In this prospective, randomized, controlled, phase 2 study, participants were recruited from 4 different hospitals in Wuhan, China. Eligible patients were histologically confirmed to have NSCLC with an EGFR-sensitive mutation (19DEL or 21L858R) and diagnosed at stage IV. Patients who had received first-line EGFR-TKIs treatment including gefitinib, erlotinib, and icotinib and achieved stable disease or partial response were enrolled after three months. Eligible participants were randomly assigned (1:1) to receive SBRT plus EGFR-TKIs or EGFR-TKIs treatment alone. In the combination-group, different tumor sites were irradiated at doses ranging from 30-50 Gy in five fractions. Considering the short duration of SBRT, the TKIs were continued during the radiotherapy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS) and safety. This study was registered at ClinicalTrials.gov, with the registration number of NCT03595644. RESULTS: Between May 4, 2018 and Dec 20, 2019, 74 patients were screened, of whom 62 patients were enrolled and randomized. The study was closed early with 62/72 patients due to slow accrual. The enrolled patients were randomly assigned to receive SBRT plus EGFR-TKI(n = 31) or EGFR-TKI alone (n = 31). One patient who was randomized to the SBRT plus EGFR-TKI group refused to receive SBRT during the treatment, and, 61 patients were included the modified intention-to-treat (mITT) analysis, with 30 in the SBRT plus EGFR-TKI and 31 in the EGFR-TKI group. As of the clinical cutoff date (Feb 14, 2022), the median follow-up was 29.4 months (IQR 6.9-38.9). The median PFS of the EGFR-TKI group and SBRT combination group was 9.0 vs 17.6 months (hazard ratio [HR] = 0.52, 95% confidence interval [95%CI], 0.31-0.89, P = 0.016). Meanwhile, the median OS was 23.2 vs 33.6 months (HR [95%CI], 0.53(0.30-0.95); P = 0.026). There was no grade 3 or greater toxicity observed in either group, the grade 2 adverse events were 50% in the EGFR-TKIs + SBRT group while the percentage was 45.2% in the EGFR-TKIs group. CONCLUSIONS: The addition of SBRT significantly delayed the onset of acquired resistance to EGFR-TKIs and prolonged the PFS and OS of patients. Radiotherapy of the primary lesion alone might be superior to metastatic sites. Further confirmatory studies are needed to confirm our findings.
引用
- Peng P, Gong J, Zhang Y, et al. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. Radiother Oncol. 2023. PMID: 37105304. doi:10.1016/j.radonc.2023.109681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。